Kyle Hogarth MD, FCCP

Dr. Kyle Hogarth is an expert in pulmonary diseases including alpha-1 anti-trypsin (AAT) deficiency. He is also involved with the minimally invasive diagnosis, management, staging, and treatment of lung cancer through bronchoscopy.

Dr. Hogarth was one of the first doctors in Illinois to work with the super dimension system an electromagnetic navigation system that uses 3-D imaging technology to detect and biopsy nodules and masses. He was the first physician in the United States to utilize the Auris Monarch platform, a robotic bronchoscope. He uses endobronchial ultrasound to biopsy lymph nodes, places stents in cancerous airways, and performs all other minimally invasive techniques to help patients with lung cancer.

Dr. Hogarth was the first physician in Illinois to perform bronchial Thermoplastic, a new FDA-approved technique to treat severe asthma. He has done the most cases in Illinois and has authored numerous publications on this topic. Dr. Hogarth's research focuses on improving the quality of life and outcomes for patients with AAT deficiency and lung cancer. He is an investigator in numerous clinical trials for these diseases and for bronchoscopy technologies.

In 2007 and 2011, he received the Department of Medicine’s Outstanding Junior Faculty Clinical Service Award, and in 2013 and 2014 the Department of Medicine’s Outstanding Clinical Service Award. In addition to his clinical and research work, Dr. Hogarth is on the editorial board for Chest -The Journal of the American College of Chest Physicians and the Proceedings of the American Thoracic Society. He is also a manuscript reviewer for the European Respiratory Journal, Lung Cancer, Respiratory Research, and 12 other journals.